Biotech entity

Roche

Company

The clearest coverage concentration is pharma: 7 of 8 stories, with the rest divided among 1 other category. Sentiment skews more negative than the wider beat, at 38% negative against 17% across all 554 Biotech stories in the same window.

Last mentioned: Jul 15, 2026

Entity pulse

Recent coverage · Roche

8 stories
6.4 avg impact
25% positive
38% negative

Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 13 percentage points.

  • 25% positive
  • 38% neutral
  • 38% negative

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Roche

The clearest coverage concentration is pharma: 7 of 8 stories, with the rest divided among 1 other category. Sentiment skews more negative than the wider beat, at 38% negative against 17% across all 554 Biotech stories in the same window. Roche is most often covered alongside Bristol Myers Squibb, which appears in 2 of these 8 stories. Across a 147-day span, the pace is roughly 0.4 stories per week. The busiest single day carried 2. Their average consequence score of 6.4 runs above the beat's 6.2 for that window. Each story carries 3.6 original sources on average, compared with 3.6 for the broader beat in this window. We currently track 8 Biotech stories that mention Roche, published between February 19, 2026 and July 15, 2026.

Stories tracked
8
Per week
0.4
Negative
38%
Sources per story
3.6

Computed from the 8 stories linked to this entity, with beat comparisons drawn from all 554 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Roche. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Data Review

    Expected first quarterly report on screening uptake and identification rates in Scotland.

  2. Earnings Call

    Management hosts a conference call to discuss 2025 performance and 2026 outlook.

  3. Financial Reporting

    XOMA files Q4 and Full Year 2025 financial results with the SEC.

  4. Pipeline Potential Report

    Industry analysis highlights organoids as a key driver of R&D efficiency.

  5. Scotland Launch

    Scotland officially begins nationwide screening for all newborns.

  6. Asset Acquisition

    Completion of a significant acquisition of royalty rights from a clinical-stage partner.

  7. Strategic Disclosure

    XOMA issues Regulation FD disclosure regarding portfolio updates.

  8. First IND via Organoid Data

    A drug candidate enters Phase I trials based primarily on organoid-derived safety data.

  9. Large-Scale Biobank Launch

    Major research consortiums establish standardized patient-derived organoid biobanks.

  10. UK NSC Recommendation

    The UK National Screening Committee begins formal review of SMA for the newborn panel.

  11. FDA Modernization Act 2.0

    Legislation passed allowing non-animal models for drug testing.

  12. Zolgensma UK Approval

    NHS England and Scotland reach deals to fund the world's most expensive gene therapy.

Stories mentioning Roche 8

Pharma Positive

Scotland Becomes First UK Nation to Launch Newborn SMA Screening Program

Scotland has officially become the first nation in the United Kingdom to implement routine newborn screening for Spinal Muscular Atrophy (SMA). This landmark public health initiative aims to identify the rare genetic condition within days of birth, enabling immediate access to life-saving gene therapies before irreversible muscle wasting occurs.

2 sources
Pharma Positive

Pipeline Potential: Mini Lab-Grown Organs Transform Drug Discovery

Mini lab-grown organs, or organoids, are transitioning from research tools to central pillars of the pharmaceutical drug development pipeline. By offering human-relevant models that outperform traditional animal testing, these 3D cultures are set to reduce clinical trial failure rates and accelerate R&D timelines.

2 sources
Pharma Neutral

Africa Reimagines Lab Infrastructure as Essential Health Security Pillar

At the Roche Africa Press Day, health leaders and the Africa CDC called for a fundamental shift in laboratory financing, moving from reactive emergency response to permanent national infrastructure. The transition is tied to the upcoming 2026 global pandemic agreement, which aims to mandate pathogen data sharing in exchange for equitable access to medical countermeasures.

2 sources

Roche is linked from 8 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.